Literature DB >> 24759829

The forgotten component in the staging and management of HIV/hepatitis C virus-coinfected patients.

Edward R Cachay1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24759829      PMCID： PMC4133564          DOI： 10.1093/cid/ciu282

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

Review 1.  HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next?

Authors:  Valérie Martel-Laferrière; Michael Wong; Douglas T Dieterich
Journal:  Clin Infect Dis       Date:  2013-10-30       Impact factor: 9.079

Review 2.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.

Authors:  Jason Grebely; Megan Oser; Lynn E Taylor; Gregory J Dore
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

3.  Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model.

Authors:  Edward R Cachay; Lucas Hill; Craig Ballard; Bradford Colwell; Francesca Torriani; David Wyles; William C Mathews
Journal:  AIDS Res Ther       Date:  2013-03-28       Impact factor: 2.250

4.  Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.

Authors:  D Grint; L Peters; C Schwarze-Zander; M Beniowski; C Pradier; M Battegay; D Jevtovic; V Soriano; J D Lundgren; J K Rockstroh; O Kirk; A Mocroft
Journal:  HIV Med       Date:  2013-07-19       Impact factor: 3.180
  4 in total
  1 in total

1.  The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.

Authors:  Edward R Cachay; David Wyles; Lucas Hill; Craig Ballard; Francesca Torriani; Bradford Colwell; Alexander Kuo; Robert Schooley; Christopher W Mathews
Journal:  Open Forum Infect Dis       Date:  2015-11-12       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.